These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30217317)

  • 1. Severity classification of Tenosynovial Giant Cell Tumours on MR imaging.
    Mastboom MJL; Verspoor FGM; Hanff DF; Gademan MGJ; Dijkstra PDS; Schreuder HWB; Bloem JL; van der Wal RJP; van de Sande MAJ
    Surg Oncol; 2018 Sep; 27(3):544-550. PubMed ID: 30217317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
    Mastboom MJL; Lips W; van Langevelde K; Mifsud M; Ng C; McCarthy CL; Athanasou NA; Gibbons CLMH; van de Sande MAJ
    Surg Oncol; 2020 Dec; 35():261-267. PubMed ID: 32932224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
    Mastboom MJL; Palmerini E; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Staals EL; Schaap GR; Jutte PC; Aston W; Gelderblom H; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; ; van de Sande MAJ
    Lancet Oncol; 2019 Jun; 20(6):877-886. PubMed ID: 31029509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.
    Takeuchi A; Nomura A; Yamamoto N; Hayashi K; Igarashi K; Tandai S; Kawai A; Matsumine A; Miwa S; Nishida Y; Nakamura T; Terauchi R; Hoshi M; Kunisada T; Endo M; Yoshimura K; Murayama T; Tsuchiya H
    BMC Musculoskelet Disord; 2019 Feb; 20(1):68. PubMed ID: 30738433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of arthroscopic excision based on the distribution of the tenosynovial giant cell tumor around knee joint.
    Yoo HJ; Nam HS; Park SB; Lee YS
    Knee; 2023 Mar; 41():360-372. PubMed ID: 36848705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of tenosynovial giant cell tumour of the foot and ankle.
    Spierenburg G; Lancaster ST; van der Heijden L; Mastboom MJL; Gelderblom H; Pratap S; van de Sande MAJ; Gibbons CLMH
    Bone Joint J; 2021 Apr; 103-B(4):788-794. PubMed ID: 33789469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function.
    Verspoor FGM; Mastboom MJL; Hannink G; van der Graaf WTA; van de Sande MAJ; Schreuder HWB
    Bone Joint J; 2019 Mar; 101-B(3):272-280. PubMed ID: 30813787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared With Adults.
    Mastboom MJL; Verspoor FGM; Uittenbogaard D; Schaap GR; Jutte PC; Schreuder HWB; van de Sande MAJ
    Clin Orthop Relat Res; 2018 Sep; 476(9):1803-1812. PubMed ID: 29494352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 12. A New Simple and Practical Clinical Classification for Tenosynovial Giant Cell Tumors of the Knee.
    Zheng K; Yu XC; Hu YC; Xu M; Zhang JY
    Orthop Surg; 2022 Feb; 14(2):290-297. PubMed ID: 34914180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of Illness Associated with Tenosynovial Giant Cell Tumors.
    Burton TM; Ye X; Parker ED; Bancroft T; Healey J
    Clin Ther; 2018 Apr; 40(4):593-602.e1. PubMed ID: 29580718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher incidence rates than previously known in tenosynovial giant cell tumors.
    Mastboom MJL; Verspoor FGM; Verschoor AJ; Uittenbogaard D; Nemeth B; Mastboom WJB; Bovée JVMG; Dijkstra PDS; Schreuder HWB; Gelderblom H; Van de Sande MAJ;
    Acta Orthop; 2017 Dec; 88(6):688-694. PubMed ID: 28787222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR imaging findings for differentiating nonhemophilic hemosiderotic synovitis from diffuse-type tenosynovial giant cell tumor of the knee.
    Ando T; Kato H; Kawaguchi M; Nagano A; Hyodo F; Matsuo M
    Jpn J Radiol; 2021 Jan; 39(1):76-83. PubMed ID: 32860160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Tenosynovial Giant Cell Tumor of the Foot and Ankle.
    Barnett JR; Rudran B; Khan A; O'Reilly-Harbidge S; Patel S; Malhotra K; Cullen N; Welck M; Aston W
    Foot Ankle Int; 2023 Oct; 44(10):1013-1020. PubMed ID: 37644900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
    Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
    Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distraction arthroplasty combined with autologous bone grafting for diffuse-type tenosynovial giant cell tumour with articular cartilage defect and subchondral bone cysts: A case report.
    Ikuta Y; Nakasa T; Sumii J; Nekomoto A; Kawabata S; Adachi N
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):483-487. PubMed ID: 36484489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments of tenosynovial giant cell tumours of the temperomandibular joint: a report of three cases and a review of literature.
    Verspoor FGM; Mastboom MJL; Weijs WLJ; Koetsveld AC; Schreuder HWB; Flucke U
    Int J Oral Maxillofac Surg; 2018 Oct; 47(10):1288-1294. PubMed ID: 29709323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark.
    Ehrenstein V; Andersen SL; Qazi I; Sankar N; Pedersen AB; Sikorski R; Acquavella JF
    J Rheumatol; 2017 Oct; 44(10):1476-1483. PubMed ID: 28765257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.